The initiative, “Change the Odds: Uniting to
Improve Cancer Outcomes” aims to enhance awareness of and access to
cancer screening, clinical trials and support in medically
underrepresented communities across the United States
The American Cancer Society (ACS) and Pfizer
Inc. (NYE: PFE) today announced the launch of “Change the Odds™:
Uniting to Improve Cancer Outcomes,” a three-year initiative to
bridge the gap in cancer care disparities. Through $15 million in
funding from Pfizer, the initiative aims to improve health outcomes
in medically underrepresented communities across the United States
by enhancing awareness of and access to cancer screenings, clinical
trial opportunities, and patient support and comprehensive
navigation. “Change the Odds” will initially focus on breast and
prostate cancer in medically underserved communities, with the
potential to expand to additional cancer types. ACS plans to engage
additional partners to extend the reach of the programmatic
activities to more individuals and deepen the tangible impact in
select communities.
“Cancer doesn’t discriminate – and neither should cancer care,”
said Chris Boshoff, Chief Oncology Officer and Executive Vice
President, Pfizer. “Everyone should have the same opportunity to
access the latest advances in care, regardless of their background
or where they live. We’re proud to partner with the American Cancer
Society on a broad, community-focused initiative to reach people
living with cancer where they are, with urgency, and connect them
to resources to receive the care they deserve.”
Breast and prostate cancer are the most common types of cancer
diagnosed among women and men in the United States, respectively.i
Incidence for both cancers continues to increase nationwideii,iii
with a greater impact for certain races and ethnicitiesiv, which
can be more pronounced in urban areas.v In addition, people living
in rural areas in the United States face barriers to accessing
cancer screening and quality care,vi leading to higher mortality
rates.vii Feelings of social isolation experienced by people living
with breast or prostate cancer are associated with poorer
outcomes,viii,ix underscoring a critical need for community-centric
approaches that are designed to make a tangible difference in
patients’ lives by addressing their whole health needs, tackling
seclusion and providing the help they need to ensure timely access
to scientific advances in care.
“Our goal of ending cancer as we know it, for everyone,
including medically underrepresented communities, can only be
attained through strong and actionable partnerships with a shared
vision like ours with Pfizer,” said Dr. Karen E. Knudsen, CEO of
the American Cancer Society. “Our collaboration will help unlock
ACS’ full potential in addressing health disparities with
measurable, sustainable and systemic solutions to deliver access to
high-quality care and treatments for every individual.”
ACS will leverage its broad network and engage on-the-ground
partners to connect individuals and promote awareness of no- and
low-cost screening and access to programs and services through
culturally sensitive outreach in communities disproportionately
impacted by breast and prostate cancer. ACS aims to accelerate
access to today’s treatments and tomorrow’s scientific advancements
to “Change the Odds” to drive sustainable solutions to help ensure
equitable outcomes for all patients.
Through ACS’ extensive evidence-based patient navigation
programs, patients will be guided through the complexities of their
cancer journey and given information to help them understand and
access recommended screening, treatments, community resources, and
emotional support. ACS will also work to empower patients and
healthcare providers in several medically underrepresented
communities with information about clinical trials and address
potential barriers to trial participation. Additionally, ACS will
work alongside its vast network of Health Equity Ambassadors to
deliver trusted cancer prevention and early detection resources and
information into each community.
For more information about “Change the Odds” please visit
www.cancer.org/ChangeTheOdds.
Key Statistics:
- According to the latest research from ACS, about 299,000 men
will be diagnosed with prostate cancer in 2024, with more than
35,000 deaths.x
- The incidence of prostate cancer is about 70% higher in Black
men than in White men.xi Black men are over two times more likely
to die from the disease than White, Hispanic or Asian
American/Pacific Islander men.xi
- Nearly 311,000 women will be diagnosed with breast cancer this
year, with more than 42,000 deaths.x
- Despite having a 4 percent lower incidence of breast cancer,
Black women with breast cancer are 40% more likely to die than
White women and twice as likely to die if they are younger than the
age of 50.xii Hispanic women are more likely to be diagnosed with
later-staged breast cancer in comparison to White women.xiii
- While there has been progress in cancer prevention, early
detection, and treatment in the United States, people who are of
lower socioeconomic status and living in rural areas have not
benefited equitably from these advances.xiv In general, survival
after a cancer diagnosis is shorter for people of all races who
have a lower socioeconomic status and who live in a more rural area
than those who do not.xiv
- Although cancer can disproportionately impact ethnic/racial
groups in both incidence and outcome, racial minorities are less
likely to be included in clinical trials.iv
- Those living in rural areas often experience transportation
challenges and other barriers to clinical trial
participation.vi
About The American Cancer Society The American
Cancer Society is a leading cancer-fighting organization with a
vision to end cancer as we know it, for everyone. For more than 100
years, we have been improving the lives of people with cancer and
their families as the only organization combating cancer through
advocacy, research, and patient support. We are committed to
ensuring everyone has an opportunity to prevent, detect, treat, and
survive cancer. To learn more, visit cancer.org or call our 24/7
helpline at 1-800-227-2345. Connect with us on Facebook, Twitter,
and Instagram.
About Pfizer Oncology At Pfizer Oncology, we are at
the forefront of a new era in cancer care. Our industry-leading
portfolio and extensive pipeline includes game-changing mechanisms
of action to attack cancer from multiple angles, including
antibody-drug conjugates (ADCs), small molecules, bispecifics and
other immunotherapies. We are focused on delivering transformative
therapies in some of the world’s most common cancers, including
breast cancer, genitourinary cancer and hematologic malignancies,
as well as melanoma, gastrointestinal, gynecological and thoracic
cancers, which includes lung cancer. Driven by science, we are
committed to accelerating breakthroughs to extend and improve
patients’ lives.
Pfizer Disclosure Notice
The information contained in this release is as of February 5,
2024. The Company assumes no obligation to update forward-looking
statements contained in this release as the result of new
information or future events or developments.
This release contains forward-looking statements about Pfizer
and the American Cancer Society’s launch of “Change the Odds:
Uniting to Improve Cancer Outcomes,” a three-year initiative which
aims to improve health outcomes in medically underrepresented
communities across the United States by enhancing awareness of and
access to cancer screenings, clinical trial opportunities, and
patient support and comprehensive navigation, that involves
substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such
statements. Risks and uncertainties include, among other things,
the uncertainties inherent in research and development, including
the ability to meet anticipated clinical endpoints, commencement
and/or completion dates for our clinical trials, regulatory
submission dates, regulatory approval dates and/or launch dates, as
well as the possibility of unfavorable new clinical data and
further analyses of existing clinical data; decisions by regulatory
authorities impacting labeling, manufacturing processes, safety
and/or other matters that could affect the availability or
commercial potential of Pfizer’s product candidates, including
development of products or therapies by other companies;
manufacturing capabilities or capacity; uncertainties regarding the
ability to obtain recommendations from vaccine technical committees
and other public health authorities and uncertainties regarding the
commercial impact of any such recommendations; the uncertainties
inherent in business and financial planning, including, without
limitation, risks related to Pfizer’s business and prospects,
adverse developments in Pfizer’s markets, or adverse developments
in the U.S. or global capital markets, credit markets, regulatory
environment or economies generally; uncertainties regarding the
success of the Accord; the impact of COVID-19 on the Company’s
business, operations and financial results; and competitive
developments.
A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2022 and in its subsequent reports on Form 10-Q,
including in the sections thereof captioned “Risk Factors” and
“Forward-Looking Information and Factors That May Affect Future
Results”, as well as in its subsequent reports on Form 8-K, all of
which are filed with the U.S. Securities and Exchange Commission
and available at www.sec.gov and www.pfizer.com.
_________________________ i American Cancer Society.
https://www.cancer.org/research/acs-research-news/facts-and-figures-2024.html#:~:text=In%20men%2C%20the%20top%203,51%25%20of%20all%20cancer%20cases.
ii American Cancer Society.
https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
iii American Cancer Society.
https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html
iv American Cancer Society. Cancer Facts & Figures for African
Americans 2022-2024 v Zahnd WE, James AS, Jenkins WD, Izadi
SR, Fogleman AJ, Steward DE, Colditz GA, Brard L. Rural-Urban
Differences in Cancer Incidence and Trends in the United States.
Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1265-1274. doi:
10.1158/1055-9965.EPI-17-0430. Epub 2017 Jul 27. PMID: 28751476;
PMCID: PMC5787045 vi Henley SJ, Jemal A. Rural Cancer
Control: Bridging the Chasm in Geographic Health Inequity. Cancer
Epidemiol Biomarkers Prev. 2018 Nov;27(11):1248-1251. doi:
10.1158/1055-9965.EPI-18-0807. PMID: 30385497; PMCID:
PMC7076627. vii Yabroff KR, Han X, Zhao J, Nogueira L, Jemal
A. Rural Cancer Disparities in the United States: A Multilevel
Framework to Improve Access to Care and Patient Outcomes. JCO Oncol
Pract. 2020 Jul;16(7):409-413. doi: 10.1200/OP.20.00352. Epub 2020
Jun 23. PMID: 32574130. viii Nature.com
https://www.nature.com/articles/s41562-023-01617-6 ix Family
structure and living arrangements as indicators of social
isolation, and prostate cancer risk - ScienceDirect x
American Cancer Society. Cancer statistics, 2024 - Siegel - 2024 -
CA: A Cancer Journal for Clinicians - Wiley Online Library xi
American Cancer Society – Cancer Facts & Figures 2024 xii
American Cancer Society.
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21754.
xiii American Cancer Society.
https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-facts-and-figures-for-hispanics-and-latinos/hispanic-latino-2021-2023-cancer-facts-and-figures.pdf
xiv American Cancer Society. American Cancer Society’s report on
the status of cancer disparities in the United States, 2023.
https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21812
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240202234166/en/
Pfizer Media Contact: +1 (212) 733-1226
PfizerMediaRelations@Pfizer.com
Pfizer Investor Contact: +1 (212) 733-4848
IR@Pfizer.com
American Cancer Society Media Contact: Ana Marquez
ana.marquez@cancer.org
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024